Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of Estrella Immunopharma, Inc. - Warrant
No Price
01.05.2026 19:24
Current Prices from Estrella Immunopharma, Inc. - Warrant
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
NASDAQ
ESLAW
USD
01.05.2026 19:24
0,13 USD
-0,02 USD
-10,79 %
Share Float & Liquidity
Free Float25,69 %
Shares Float9,1 M
Shares Outstanding35,42 M
Company Profile for Estrella Immunopharma, Inc. - Warrant Share
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
